Clinical Trial Update: A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ruxolitinib in combination with corticosteroids for steroid-refractory acute graft-versus-host disease has completed and results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Graft-versus-host Disease (GVHD) | Phase 2 | Status: COMPLETED | Results posted: 2019-08-20